Literature DB >> 11550996

PPARS in inflammation, atherosclerosis and thrombosis.

H Duez1, J C Fruchart, B Staels.   

Abstract

PPARs are transcription factors which regulate lipid and lipoprotein metabolism, glucose homeostasis and cellular differentiation. PPARalpha enhances fatty acid oxidation whereas PPARgamma promotes adipogenesis and fatty acid storage in adipose tissue. Both PPARalpha and PPARgamma improve glucose homeostasis. PPARalpha and PPARgamma are activated by the pharmacological agents fibrates and glitazones respectively, and by natural fatty acid derivatives, including inflammation mediators. PPARs are expressed in the different cell types of human atherosclerotic lesions where they regulate the expression of genes involved in the inflammatory response and lipid homeostasis. PPARs modulate the recruitment and adhesion of leukocytes and monocytes to the atherosclerotic lesion. PPARs furthermore control macrophage lipid homeostasis through their action on scavenger receptors and by regulating genes involved in the first steps of the reverse cholesterol transport pathway. Finally, PPARs regulate genes controlling thrombogenicity associated with plaque rupture. These observations suggest that PPARs modulate atherosclerosis development by acting at both metabolic and vascular levels. This review will essentially focus on the functions of PPARalpha and PPARgamma in immunoregulation, vascular inflammation and thrombosis associated to atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11550996     DOI: 10.1177/174182670100800402

Source DB:  PubMed          Journal:  J Cardiovasc Risk        ISSN: 1350-6277


  14 in total

Review 1.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.

Authors:  Ebele C Chira; Timothy S McMillen; Shari Wang; Antonio Haw; Kevin D O'Brien; Thomas N Wight; Alan Chait
Journal:  Atherosclerosis       Date:  2007-01-09       Impact factor: 5.162

3.  Formononetin inhibited the inflammation of LPS-induced acute lung injury in mice associated with induction of PPAR gamma expression.

Authors:  Zhanqiang Ma; Weiwei Ji; Qiang Fu; Shiping Ma
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

Review 4.  The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity.

Authors:  Francesco S Celi; Alan R Shuldiner
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

5.  Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.

Authors:  P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps
Journal:  PPAR Res       Date:  2010-02-28       Impact factor: 4.964

6.  A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.

Authors:  Olivier F Bertrand; Paul Poirier; Josep Rodés-Cabau; Stéphane Rinfret; Lawrence Title; Vladimir Dzavik; Madhu Natarajan; Juan Angel; Nuria Batalla; Natalie Alméras; Olivier Costerousse; Robert De Larochellière; Louis Roy; Jean-Pierre Després
Journal:  Can J Cardiol       Date:  2009-09       Impact factor: 5.223

7.  Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases.

Authors:  Ajit A Kulkarni; Collynn F Woeller; Thomas H Thatcher; Sesquile Ramon; Richard P Phipps; Patricia J Sime
Journal:  PPAR Res       Date:  2012-06-18       Impact factor: 4.964

8.  The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects.

Authors:  S L Spinelli; J J O'Brien; S Bancos; G M Lehmann; D L Springer; N Blumberg; C W Francis; M B Taubman; R P Phipps
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

9.  Regulation of Lymphocyte Function by PPARgamma: Relevance to Thyroid Eye Disease-Related Inflammation.

Authors:  G M Lehmann; T M Garcia-Bates; T J Smith; S E Feldon; R P Phipps
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

10.  The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice.

Authors:  W Wallace Harrington; Christy S Britt; Joan G Wilson; Naphtali O Milliken; Jane G Binz; David C Lobe; William R Oliver; Michael C Lewis; Diane M Ignar
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.